Outcome Measures in Medication Trials for Substance Use Disorders

Current Treatment Options in Psychiatry

Volumn 2, Issue 2, 2015, Pages 113-121

  McCann, David J ^a   Ramey, Tatiana ^a   Skolnick, Phil ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Abstinence; Addiction; Clinical endpoints; Drugs of abuse; Pharmacotherapies; Substance use disorders

Indexed keywords

EID: 84951843743     PISSN: None     EISSN: 21963061     Source Type: Journal    
DOI: 10.1007/s40501-015-0038-5     Document Type: Review

References (31)

1. Pollock JD, Koustova E, Hoffman A, Shurtleff D, Volkow ND. Treatments for nicotine addiction should be a top priority. Lancet. 2009;374:513–4.
2. Fibiger HC. Psychiatry, the pharmaceutical industry, and the road to better therapeutics. Schizophr Bull. 2012;38:649–50.
3. Brady LS, Insel TR. Translating discoveries into medicine: psychiatric drug development in 2011. Neuropsychopharmacology. 2012;37:281–3.
4. The Development of Medication for the Treatment of Opiate and Cocaine Addictions. Washington, D.C., National Academy Press; 1995.
5. Acri JB, Skolnick P. Pharmacotherapy of substance use disorders. In: Charney D, Nestler E, Sklar P, Buxbaum J, editors. Neurobiology of mental illness. 4th ed. London: Oxford University Press; 2013. p. 235–45.
6. Falk D, Wang XQ, Liu L, Fertig J, Mattson M, Ryan M, et al. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res. 2010;34:2022–34.
7. Medical Review of Vivitrol. Rockville, MD: U.S. Government, 2006.
8. Mochly-Rosen D, Zakhari S. What did we learn from the French (paradox)? Alcohol Res Health. 2010;33:76–86.
9. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.
10. Winchell C, Rappaport BA, Roca R, Rosebraugh CJ. Reanalysis of methamphetamine dependence treatment trial. CNS Neurosci Ther. 2012;18:367–8. In the absence of published guidelines, this commentary provides a valuable insights on current FDA views on clinical trial endpoints for stimulant use disorders.
11. McCann DJ, Li SH. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther. 2012;18:414–8. A novel analysis that weights the duration of end of study abstinence abstinence beyond a predefined minimum threshold of success. For example, the number of weeks a subject achieves abstinence beyond a set threshold of two weeks. This method appears to confer greater sensitivity than a traditional success/failure analysis.
12. Koob GF. Negative reinforcement in drug addiction: the darkness within. Curr Open Neurobiology. 2013;23:559–63.
13. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engle J Med. 2013;368:341–50.
14. Scott CK, Dennis ML, Laudet A, Funk RR, Simeone RS. Surviving drug addiction: the effect of treatment and abstinence on mortality. Am J Public Health. 2011;101:737–44.
15. Carroll KM, Kiluk BD, Nich C, DeVito EE, Decker S, LaPaglia D, et al. Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes. Drug Alcohol Depend. 2014;137:3–19. This review uses pooled data from five randomized clinical trials of cocaine dependence to explore the sensitivities of multiple outcome measures and general functioning during follow-up.
16. Kiluk BD, Nich C, Witkiewitz K, Babuscio TA, Carroll KM. What happens in treatment doesn't stay in treatment: cocaine abstinence during treatment is associated with fewer problems at follow-up. J Consult Clin Psycho. 2014;82:619–27. By modeling the data described in Carroll, et al. (15), these investigators provide evidence that within-treatment abstinence from cocaine provides benefit that extend beyond the frequency of drug use.
17. Crits-Cristoph P, Gallop R, Connolly Gibbons MB, Sadicario J, Woody G. Measuring outcome in the treatment of cocaine dependence. J Alcohol Drug Depend. 2013;1:1–8.
18. Jayaram-Lindstrom N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry. 2008;165:1442–8.
19. Mariani JJ, Pavlicova M, Bisaga A, Nunes EV, Brooks DJ, Levin FR. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Boil Psychiatry. 2012;72:950–6.
20. Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry. 2013;70:1338–46.
21. Donovan DM, Bigelow GE, Brigham GS, Carroll KM, Cohen AJ, Gardin JG, et al. Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction. 2012;107:694–708.
22. Negus SS. Henning field J, Agonist medications for the treatment of cocaine use disorder. Neuropsychopharmacology advanced online publication, 7 January 2015; doi:10.1038/npp2014.322
23. Martin CS, Langenbucher JW, Chung T, Sher KJ. Truth or consequences in the diagnosis of substance use disorders. Addiction. 2014;109:1773–8.
24. Lai H, Stitzer M, Treisman G, Moore R, Brinker J, Gerstenblith G, et al. Reduction in cocaine use is associated with less endothelial damage in African Americans: a preliminary study. J Addiction Med 2015. Provides preliminary evidence that levels of endothelin-1 (ET-1) could represent a biomarker to examine longitudinal changes in cocaine use.
25. Saez CG, Olivares P, Pallavicini J, Panes O, Moreno N, Massardo T, et al. Increased number of circulating endothelial cells and plasma markers of endothelial damage in chronic cocaine users. Thromb Res. 2011;128:e18–23.
26. Chong AY, Blann AD, Lip GY. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM. 2003;96:253–67.
27. Kloner RA, Hale S, Alker K, Rezkalla S. The effects of acute and chronic cocaine use on the heart. Circulation. 1992;85:407–19.
28. Benzaquen BS, Cohen V, Eisenberg MJ. Effects of cocaine on the coronary arteries. Am Heart J. 2001;142:402–10.
29. Lai S, Lai H, Meng Q, Tong W, Vlahov D, Celentano D, et al. Effect of cocaine use on coronary calcium among black adults in Baltimore, Maryland. Am J Cardiol. 2002;90:326–8.
30. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126.
31. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry. 2014;13:28–35.